INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo VITA FORCE LADYVITE TABLETS

SCHEDULING STATUS:
Not scheduled

PROPRIETARY NAME
(and dosage form):

VITA FORCE LADYVITE TABLETS

COMPOSITION:
Each tablet contains:
Vitamin A 2 000 IU
Vitamin B1 5 mg
Vitamin B2 5 mg
Vitamin B6 100 mg
Vitamin B12 25 µg
Vitamin C 100 mg
Vitamin D 50 IU
Vitamin E 50 IU
Biotin 25 µg
Calcium D Pantothenate 50 mg
Folic Acid 250 µg
Nicotinamide 50 mg
Dicalcium Phosphate 100 mg
Dolomite 60 mg
Ferrous Fumarate 5 mg
Zinc Gluconate 10 mg
Calcium AAC 6 mg
Chromium AAC 100 µg
Copper AAC 2 mg
Iron AAC 18 mg
Magnesium AAC 15 mg
Manganese AAC 10 mg
Phosphorus AAC 18 mg
Potassium AAC 6 mg
Selenium AAC 5 mg
Zinc AAC 18 mg
AAC - Amino Acid Chelate

PHARMACOLOGICAL CLASSIFICATION:
A.22.1.4 Vitamins. Other

PHARMACOLOGICAL ACTION:
Vitamin and mineral supplementation.

INDICATIONS:
Vitaforce Ladyvite is indicated as a multivitamin and mineral supplement especially for women where a poor dietary intake of the relevant vitamins and minerals exists.

CONTRA-INDICATIONS:
Hypersensitivity to any of the ingredients.

Iron salts should not be given to patients receiving repeated blood transfusions.

Copper should not be used in patients with hepatolentricular degeneration (Wilson's disease)

Vitamin B6 reduces the effects of levodopa and this product should not be administered to patients receiving levodopa medication.

WARNINGS
Hypervitaminosis A may occur on the administration of excessive amounts of Vitamin A over long periods.

Iron overload may occur as a result of prolonged administration of doses in excess of those recommended.

In patients receiving oral iron therapy, additional parenteral administration of iron may result in iron overloading and toxicity.

A dose of as little as 1 g of iron should be considered toxic in children.

DOSAGE AND DIRECTIONS FOR USE:
One tablet to be taken once or twice daily after food.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Iron
: Gastro-intestinal discomfort, diarrhoea, constipation and vomiting may occur.
Side-effects can be reduced by taking it with, or immediately after food.
As a result of iron therapy, stools may become darkened or black in colour.
Care should be taken when given to patients with iron storage or iron absorption diseases, haemoglobinopathies or existing gastro-intestinal disease.
The absorption of iron salts and tetracyclines is diminished when taken concomitantly by mouth.
If treatment with both is required, the iron salt should be administered three hours before or two hours after the tetracycline.
The absorption of iron salts is also decreased in the presence of antacids or when taken with tea.
Iron salts appear to reduce the effects of penicillamine.

Vitamin B
6 reduces the effects of levodopa.

Vitamin C: Large doses may cause diarrhoea and other gastro-intestinal disturbances and are associated with the formation of renal calcium oxalate calculi.
Doses of 600 mg or more daily have a diuretic action.
Tolerance may be induced in patients taking high doses.
Vitamin C should be given with care to patients with hyper-oxaluria.
Patients with gout and/or a tendency to form kidney stones may be at increased risk with extended use.
Diabetics taking more than 500 mg per day may obtain false readings in their urinary glucose tests.

Zinc: Concurrent administration might diminish the effect of penicillamine.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
The treatment of overdosage is symptomatic and supportive.

The specific treatment of acute iron overdosage is desferroxamine.

CONDITIONS OF REGISTRATION:
As imposed by the Council.

IDENTIFICATION:
Orange speckled, oblong tablet

PRESENTATION:
Packs of 60 tablets

STORAGE INSTRUCTIONS:
Store below 25°C

Keep out of reach of children.

REFERENCE NUMBER:
T1252 (Act 101/1965)

NAME AND BUSINESS ADDRESS OF THE APPLICANT:
Pharma Natura
(PTY) LTD.
816 Fifth Street, Wynberg, Sandton,
Transvaal.

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
30 November 1992

995A0295 842630/94

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996,1997,1998